> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Determined for Anacor Pharma’s Eucrisa
- URL: https://www.fdaweb.com/regulatory-review-determined-for-anacor-pharmas-eucrisa/
- Published: 2019-02-13T12:00:00.000Z
- Updated: 2026-09-15T01:04:13.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5143373

*Federal Register* notice: FDA has determined the regulatory review period for Anacor Pharmaceuticals’ Eucrisa (crisaborole), indicated for topical treatment of mild to moderate atopic dermatitis in patients two years of age and older. The regulatory review period was determined to be 3,121 days, including 2,778 days that occurred during the testing phase and 343 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-02-12/pdf/2019-01956.pdf?ref=fdaweb.com).